Global Patent Index - EP 3368546 A4

EP 3368546 A4 20190626 - SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Title (en)

SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Title (de)

GEGEN SSTR GERICHTETE KONJUGATE SOWIE PARTIKEL UND FORMULIERUNGEN DAVON

Title (fr)

CONJUGUÉS CIBLÉS SSTR, ET SES PARTICULES ET FORMULATIONS

Publication

EP 3368546 A4 20190626 (EN)

Application

EP 16860972 A 20161028

Priority

  • US 201562247336 P 20151028
  • US 201662304856 P 20160307
  • US 2016059529 W 20161028

Abstract (en)

[origin: WO2017075495A1] Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

IPC 8 full level

C07K 14/00 (2006.01); A61K 31/436 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP US)

A61K 31/404 (2013.01 - EP US); A61K 31/436 (2013.01 - EP US); A61K 31/506 (2013.01 - EP US); A61K 31/513 (2013.01 - EP US); A61K 31/5365 (2013.01 - EP US); A61K 31/655 (2013.01 - EP US); A61K 31/7048 (2013.01 - EP US); A61K 45/06 (2013.01 - US); A61K 47/64 (2017.07 - US); A61K 47/6937 (2017.07 - US); A61K 51/083 (2013.01 - US); A61P 35/00 (2017.12 - EP US); C07K 14/72 (2013.01 - EP US)

Citation (search report)

  • [XP] WO 2016004048 A2 20160107 - BLEND THERAPEUTICS INC [US]
  • [Y] US 2015196673 A1 20150716 - NORENBERG JEFFREY P [US]
  • [A] WO 2014106208 A1 20140703 - BLEND THERAPEUTICS INC [US]
  • [Y] SHUANG HE ET AL: "Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates", DRUG DELIVERY., vol. 23, no. 1, 28 May 2014 (2014-05-28), US, pages 285 - 296, XP055586960, ISSN: 1071-7544, DOI: 10.3109/10717544.2014.911991
  • [Y] LI-CHUN SUN ET AL: "Somatostatin Receptor-Targeted Anti-Cancer Therapy", CURRENT DRUG DELIVERY, vol. 8, no. 1, 1 January 2011 (2011-01-01), NL, pages 2 - 10, XP055586965, ISSN: 1567-2018, DOI: 10.2174/156720111793663633
  • [Y] ANONYMOUS: "Press Release: Blend Therapeutics Presents Preclinical Data for Lead Pentarin(TM) Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer", 21 April 2015 (2015-04-21), XP055586945, Retrieved from the Internet <URL:http://www.tarvedatx.com/pr_04212015_2.html> [retrieved on 20190508]
  • [Y] PETER HOFLAND: "Improving Tumor Targeting Through Nanoparticle Encapsulation of Miniaturized Biologic Drug Conjugates", 15 May 2015 (2015-05-15), XP055586943, Retrieved from the Internet <URL:https://adcreview.com/news/improving-tumor-targeting-through-nanoparticle-encapsulation-of-miniaturized-biologic-drug-conjugates/> [retrieved on 20190508]
  • [T] BRIAN H. WHITE ET AL: "Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 5, 8 February 2019 (2019-02-08), pages 2708 - 2719, XP055586069, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b02036
  • [T] MARCO LELLE ET AL: "Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate", MOLECULAR PHARMACEUTICS, vol. 12, no. 12, 2 November 2015 (2015-11-02), US, pages 4290 - 4300, XP055586951, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.5b00487
  • See references of WO 2017075495A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2017075495 A1 20170504; AU 2016343817 A1 20180510; AU 2016343817 B2 20210527; AU 2021215260 A1 20210902; CA 3001712 A1 20170504; CN 108473538 A 20180831; CN 108473538 B 20220128; EP 3368546 A1 20180905; EP 3368546 A4 20190626; HK 1259311 A1 20191129; JP 2018535212 A 20181129; JP 7057278 B2 20220419; US 11160871 B2 20211102; US 2018221499 A1 20180809; US 2022096646 A1 20220331

DOCDB simple family (application)

US 2016059529 W 20161028; AU 2016343817 A 20161028; AU 2021215260 A 20210813; CA 3001712 A 20161028; CN 201680076387 A 20161028; EP 16860972 A 20161028; HK 19101677 A 20190130; JP 2018521977 A 20161028; US 201615770513 A 20161028; US 202117490692 A 20210930